NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer

I confirm that:

- I agree with the content of the statement submitted by **Breakthrough Breast cancer** and consequently I will not be submitting a personal statement.

Name: Dr Caroline Dalton.....

Signed:.....

Date: 03/07/2013.....